Vistra's Growth Offsets Face Execution Test

What happened

Sentiment remains anchored on Vistra's ability to convert AI-related power demand into contracted earnings, though the article's Buy stance glosses over near-term execution risk. Q2 adjusted EBITDA rose over 30% on strong Texas and PJM generation, and management reaffirmed 2026 guidance at or above the midpoint, consistent with the latest filings. The Cogentrix acquisition and 20-year Meta PPAs are intended to offset softer ERCOT fundamentals, but the deal adds leverage and dilutes the pace of share buybacks that had previously supported EPS. Master report modeling shows the shares are fairly valued at $146.70 with base-case implied value of $155, implying limited upside until Cogentrix closes and Meta deliveries begin on schedule in late 2026. The real risk is not demand but timing: if either milestone slips, the market's premium for contracted AI capacity compresses without a corresponding cash-flow cushion.

Implication

Investors should treat Vistra as a show-me story rather than a pure AI beneficiary. The stock already prices a successful Cogentrix close and on-time Meta startup, but both remain unproven and could slip. Given capped PJM pricing and leverage from the acquisition, the asymmetry is unattractive at current levels. A more compelling entry exists near $135, where the hedge-protected cash flow and capital returns provide better downside support. We would wait for observable proof of the two key catalysts before adding risk.

Thesis delta

The article's Buy rating adds no new information beyond what was in the Q2 filing and does not alter the WAIT rating. It correctly identifies that Cogentrix and Meta can offset ERCOT softness, but overstates the near-term impact by ignoring the deal's leverage and buyback dilution. The core thesis remains unchanged: Vistra is fundamentally solid but not mispriced at $146.70, with upside dependent on late-2026 execution milestones.